Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from BeiGene Ltd ( (HK:6160) ) is now available.
BeOne Medicines Ltd. reported a significant financial turnaround for the first half of 2025, with total revenues increasing by 44.7% to approximately US$2.43 billion compared to the same period in 2024. The company achieved a net income of US$95.6 million, a substantial improvement from a net loss of US$371.6 million in the previous year, driven by a notable rise in product revenue and controlled operating expenses.
The most recent analyst rating on (HK:6160) stock is a Hold with a HK$200.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
Average Trading Volume: 6,431,709
Technical Sentiment Signal: Buy
Current Market Cap: HK$293.1B
Find detailed analytics on 6160 stock on TipRanks’ Stock Analysis page.